TGFB1 and Alzheimer disease: In AD, SMAD2 is also a part of the TGFβ/SMAD2/STAT3 signaling pathway which is activated by APOE, the important risk factor for AD, and increases the amyloidogenic processing of APP leading to Aβ formation and contributes to cognitive decline [553].